Job Trends
Looking for a biopharma job in Pennsylvania? Check out the BioSpace list of nine companies hiring life sciences professionals like you.
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Career Advice
With leaner teams and tighter budgets, senior leaders can face tremendous strain as they juggle increased workloads and leadership responsibilities. In this column, Kaye/Bassman’s Michael Pietrack discusses how pressure builds and what can ease it.
THE LATEST
Along with lampalizumab, Roche announced it was culling several drug programs in its latest financial filing.
This is a market like the world has never seen.
AbbVie provided an unexpectedly strong 2018 guidance revision, largely built on the new corporate tax rate.
The FDA’s Breakthrough Therapy Designation for balovaptan was primarily based on efficacy findings in the VANILLA study, a Phase II trial of balovaptan in adults with ASD.
Only a week after Sanofi ponied up $11.6B to buy Waltham, Massachusetts-based Bioverativ, the French drugmaker is buying Ghent, Belgium-based Ablynx for $4.8B.
Sanofi has announced major restructuring, which will involve about 400 job cuts in the U.S.
Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies.
The company will open a new $11.6 million plant in Green County.
The medical device manufacturer will soon call Berkeley County home.
Amneal is planning an expansion of its New York facilities that will create hundreds of jobs as it and Impax Labs near completion of a planned merger.